Erika Graul
Nurse Practitioner · Carson City, NVNPI 1396881256
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 415 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 415 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$828
- Boehringer Ingelheim$785
- Mylan Specialty L.p.$721
- Sanofi$537
- plus $2K from 31 others
What the payments were for
- Food & beverage$7,92597%
- Education$2613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 117 | $1,801 |
| AstraZeneca | 43 | $1,036 |
| Regeneron Healthcare Solutions, Inc. | 41 | $828 |
| Boehringer Ingelheim | 44 | $785 |
| Mylan Specialty L.p. | 38 | $721 |
| Sanofi | 22 | $537 |
| Harmony Biosciences LLC | 12 | $332 |
| United Therapeutics Corporation | 11 | $263 |
| Insmed, Inc. | 11 | $215 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $196 |
| Sanofi-aventis U.S. LLC | 3 | $179 |
| Viatris Specialty LLC | 8 | $169 |
| Baxter Healthcare | 7 | $145 |
| Grifols USA, LLC | 5 | $97 |
| Inspire Medical Systems, Inc. | 4 | $97 |
| Mallinckrodt Hospital Products Inc. | 4 | $96 |
| Axsome Therapeutics, Inc. | 4 | $71 |
| Verona Pharma, Inc. | 3 | $69 |
| Actelion Pharmaceuticals US, Inc. | 2 | $51 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Electromed, Inc. | 2 | $42 |
| Novartis | 2 | $40 |
| Bayer | 2 | $40 |
| Tactile Systems Technology Inc | 1 | $32 |
| Johnson & Johnson | 2 | $32 |
| Merck | 1 | $29 |
| Lilly USA, LLC | 2 | $28 |
| Medtronic | 1 | $26 |
| Philips North America LLC | 2 | $25 |
| Genentech USA, Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Amgen | 1 | $18 |
| Breas Medical, Inc. | 1 | $15 |
| Itamar Medical Inc | 1 | $12 |
| 3b Medical, Inc. | 1 | $7 |
How this compares
$8,186 in reported general payments places this provider in the 95th percentile of 933 nurse practitioner providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 242 | $222,373 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 101 | $76,262 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $28,990 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $25,364 |
| Spiriva RespimatTiotropium Bromide | 27 | $18,855 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $15,862 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 348 | $14,102 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $14,084 |
| Advair DiskusFluticasone Propion/Salmeterol | 43 | $9,086 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $6,088 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,339 |
| Ventolin HfaAlbuterol Sulfate | 50 | $4,386 |
| Wixela InhubFluticasone Propion/Salmeterol | 38 | $3,536 |
| Arnuity ElliptaFluticasone Furoate | 13 | $3,363 |
| Fluticasone Propionate | 36 | $2,565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,801 | $286,178373 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,036 | $81,601120 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $785 | $34,71743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 nurse practitioner providers in Nevada.
Other nurse practitioner in Carson City
- Gladys DolorCarson City$13K
- Ashley VazeenCarson City$8K
- Charina TosteHenderson$393K
- Melanie SpeedLas Vegas$80K
- Shelley MilesLas Vegas$34K
- Nasslynne LenzLas Vegas$32K
- Shannon SouthwickLas Vegas$32K
- Bonnie KwanLas Vegas$30K
- Amanda RalphLas Vegas$26K
- Teodoro AgtayLas Vegas$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.